Medtronic plc (MDT) Factsheet
Medtronic plc (MDT) Stock Analysis
Analysis from 10-Q filed 2025-11-25. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 6.5%. FCF margin 15.2%. D/E 0.6x. Source: 10-Q filed 2025-11-25.
| Metric | Value | Context |
|---|---|---|
| ROIC | 6.5% | Below expectations |
| FCF Margin | 15.2% | Strong cash generation |
| Debt/Equity | 0.6x | Moderate leverage |
ROIC 6.5% — Top 50% of sector peers. FCF margin 15.2% — Top 5%.
Explore Medtronic plc: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for MDT: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Medtronic plc earns 6.5% ROIC, Top 50% in Healthcare
ROIC TTM 6.5%, sector median -2.8%, Top 50%. DuPont: NOPAT margin 14.2% × asset turnover 0.4x. Gross margin 64.9%. Operating margin 17.0%. Source: 10-Q filed 2025-11-25.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 6.5% | Warning | Above sector median of -2.8% |
| Return on Equity (ROE) | 9.5% | Adequate | Moderate equity returns |
| Gross Margin | 64.9% | Excellent | Strong pricing power |
| Operating Margin | 17.0% | Good | Efficient operations |
Cash Flow: Medtronic plc generates $5.4B FCF at 15.2% margin, positive NaN/8 quarters
FCF TTM $5.4B. FCF margin 15.2%, Top 5%. OCF/Net income 1.6x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-25.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 15.2% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $5.4B | Good | Positive cash generation |
| OCF/Net Income | 1.6x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Medtronic plc at 0.6x leverage
Debt/Equity 0.6x. Total debt $28.1B, cash & investments $8.4B. Source: 10-Q filed 2025-11-25.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.6x | Good | Moderate leverage |
| Net Cash Position | $-19.7B | Warning | Net debt position |
Valuation: Medtronic plc trades at 28.0x earnings
P/E 28.0x. EV/Sales 4.2x. FCF yield 4.2%. Dividend yield 2.8%. Source: 10-Q filed 2025-11-25.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| P/E Ratio | 28.0x | Adequate | Premium valuation |
| EV/Sales | 4.2x | Good | Growth premium priced in |
| FCF Yield | 4.2% | Good | Lower cash yield |
| Dividend Yield | 2.8% | Adequate | Growth focus over income |
Capital Allocation: Medtronic plc returns 3.5% shareholder yield
Total shareholder yield 3.5% (div 2.8% + buyback 0.7%). Capital returned $4.5B TTM. Source: 10-Q filed 2025-11-25.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.5% | Good | Dividend + buyback yield combined |
| Buyback Yield | 0.7% | Adequate | Minimal buyback activity |
| Total Capital Returned (TTM) | $4.5B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 6.5% | Top 50% | - |
| Free Cash Flow Margin | 15.2% | Top 5% | - |
| Gross Margin | 64.9% | Top 50% | 1.0x above |
| Operating Margin | 17.0% | Top 25% | 7.5x above |
| Return on Equity (ROE) | 9.5% | Top 50% | - |
| P/E Ratio | 28.0x | N/A | - |
Financial Scorecard
| Metric | MDT | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 6.5% | Warning | Top 50% of sector (median: -2.8%) |
| Free Cash Flow Margin | 15.2% | Good | Top 5% of sector (median: 0.0%) |
| Gross Margin | 64.9% | Excellent | Top 50% of sector (median: 63.7%) |
| Debt to Equity Ratio | 57.3% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 28.0x | Adequate | Growth premium |
| Free Cash Flow Yield | 4.2% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is Medtronic plc's Return on Invested Capital (ROIC)?
Medtronic plc (MDT) has a trailing twelve-month Return on Invested Capital (ROIC) of 6.5%. Sector median -2.8%. Source: 10-Q filed 2025-11-25.
Q: What is Medtronic plc's Free Cash Flow Margin?
Medtronic plc (MDT) has a free cash flow margin of 15.2%, generating $5.4 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-25.
Q: What is Medtronic plc's P/E ratio and how does it compare to peers?
Medtronic plc (MDT) trades at a P/E ratio of 28.0x, which is above the sector median of N/A. EV/Sales 4.2x. FCF yield 4.2%. Source: 10-Q filed 2025-11-25.
Q: Does Medtronic plc pay a dividend?
Medtronic plc (MDT) currently pays a dividend yield of 2.8%. Total shareholder yield (dividend + buybacks) 3.5%. Source: 10-Q filed 2025-11-25.
Q: How much debt does Medtronic plc have?
Medtronic plc (MDT) has a debt-to-equity ratio of 0.6x with total debt of $28.1 billion. Net debt $19.7 billion. Source: 10-Q filed 2025-11-25.
Q: What is Medtronic plc's revenue and earnings growth?
Medtronic plc (MDT) grew revenue by 6.9% year-over-year. EPS +9.1% YoY. Source: 10-Q filed 2025-11-25.
Q: Is Medtronic plc buying back stock?
Medtronic plc (MDT) repurchased $874.0 million of stock over the trailing twelve months. This represents a buyback yield of 0.7%. Source: 10-Q filed 2025-11-25.
Q: How does Medtronic plc compare to competitors in Healthcare?
Compared to other companies in Healthcare, Medtronic plc (MDT) shows: ROIC 6.5%, sector median -2.8% (Top 50%). FCF margin 15.2%, sector median 0.0% (Top 5%). Gross margin 64.9%, 1.2pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Medtronic plc?
No quantitative warning flags fired for Medtronic plc (MDT) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2025-11-25.
Data Source: Data sourced from 10-Q filed 2025-11-25. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.